Matches in SemOpenAlex for { <https://semopenalex.org/work/W21811316> ?p ?o ?g. }
- W21811316 abstract "Background: Oral antigoagulation treatment (OAT) with warfarin have a narrow therapeutic window and patients exhibit a highly variable doseresponse that is attributable to genetic, disease-related,and environmental factors as well as prescription and nonprescription drugs, dietary vitamin K and alcohol. The effect of warfarin treatement on blood coagulation is measured using international normalized ratio (INR). Monitoring and tight control of anticoagulation treatment reduces the risk of both thrombosis and bleeding. The time in therapeutic range (TTR) has been validated as a quality indicator of the anticoagulation treatment given, correlating inversely to complication frequencies. The Swedish national quality registry for atrial fibrillation and anticoagulation (AuriculA) was founded in 2006 and has by August 2011 enrolled 68,000 patients, close to 40 % of all patients on anticoagulation in Sweden. Patients with end stage renal disease are at high risk for both bleeding and thrombosis and even a moderate decrease in glomerular filtration rate (GFR) is associated with thromboembolic and bleeding complications. Impaired kidney function has also been shown to be associated with a greater need of warfarin dose adjustment, poor TTR, and an increased risk of bleeding in patients taking warfarin. New anticoagulants, most of them eliminated by renal route, can be administered in a fix dose, have few drug and no dietary interactions, has been shown to be at least inferior and in some cases superior to OAT with warfarin. Methods: The Anticoagulation Clinic in Malmo participates in AuriculA, and uses this registry for prospective follow-up and as a tool for OAT dosage. This thesis has utilized data from AuriculA for epidemilogical analysis of impaired kidney function, using two equations for estimated glomerular filtration rate (eGFR), TTR, and the correlation of these two markers to major bleeding and thrombo-embolic events. Results: In Paper I, TTR in 18391 patients in the whole Swedish AuriculA population was 76.2%. Compared to recent prospective randomized trials of warfarin treatment, TTR in the AuriculA population was higher. Adherence to treatment, as measured by TTR, was higher in elderly patients with a significant correlation with increasing age. In 4273 patients from two centers in AuriculA the frequency of major bleedings and venous/arterial thromboembolism were 2.6 % and 1.7 % and for atrial fibrillation (AF), 2.6 % and 1.4 %, per treatment year respectively. In Paper II, the fraction of 2603 AF patients on warfarin with eGFR 3.0 (p<0.001 for both). There was no correlation between age, eGFR and thromboembolic events. The prevalence of eGFR <45ml/min/1.73m2 was 52% in patients aged ≥75 years with major bleeding. eGFR levels <30 ml/min/1.73m2 were particularly associated with high risk of bleeding in elderly patients. No correlation between eGFR and thromboembolic events was seen. In Paper IV, 397 patients on OAT with warfarin, there was a positive correlation between results from the point-of-care device (POC) CoaguChek XS and the Owren-type PT assay for INR measurement (r=0.94;p<0.001) and concordance of 88.2%. In patients with 152 double samples analyzed with the CoaguChek XS, a positive correlation of 0.99 was seen; p<0.001. Conclusions: The quality of OAT with warfarin in Sweden is high and comparable to prospective randomized trials of warfarin treatment. Complications were low, probably due to the organization of anticoagulation treatment in Sweden, although the AuriculA dosing algorithm could have contibuted by keeping dosing regimens consistent over all centers. The POC-device CoaguChek XS presents reproducible results, highly comparable with Owren PT at therapeutic levels of INR, offering a more convenient method of monitoring, compared to regular venous INR measurement in patients on OAT with warfarin. Severe renal impairment is common among AF patients on OAT with warfarin, especially at higher ages, indicating one important difference between a ‘real world’ clinical population and those of randomized controlled trials of new oral anticoagulant drugs, where patients with severe renal failure (eGFR <30 ml/min/1.73 m2) were excluded. Given the strong correlation between eGFR and major bleeding events in patients on anticoagulation treatment demonstrated in Paper III, caution is advised in the upcoming era of new oral anticoagulants with elimination by renal route. Monitoring of renal function should be implemented in clinical practice for AF patients treated with new anticoagulants eliminated by the kidneys and registries like AuriculA can be used for prospective follow-up of these patients." @default.
- W21811316 created "2016-06-24" @default.
- W21811316 creator A5024506636 @default.
- W21811316 date "2011-01-01" @default.
- W21811316 modified "2023-09-24" @default.
- W21811316 title "Oral anticoagulation treatment in atrial fibrillation - To bleed or not to bleed, that is the question" @default.
- W21811316 cites W138378723 @default.
- W21811316 cites W1492931178 @default.
- W21811316 cites W1501820105 @default.
- W21811316 cites W1549602366 @default.
- W21811316 cites W1550111394 @default.
- W21811316 cites W1559899200 @default.
- W21811316 cites W1576662610 @default.
- W21811316 cites W1586488555 @default.
- W21811316 cites W1738640266 @default.
- W21811316 cites W1759894762 @default.
- W21811316 cites W1804375307 @default.
- W21811316 cites W1873771693 @default.
- W21811316 cites W1926960346 @default.
- W21811316 cites W1964366892 @default.
- W21811316 cites W1964564448 @default.
- W21811316 cites W1967136383 @default.
- W21811316 cites W1967792178 @default.
- W21811316 cites W1972357677 @default.
- W21811316 cites W1972409937 @default.
- W21811316 cites W1979862336 @default.
- W21811316 cites W1989090496 @default.
- W21811316 cites W1990052626 @default.
- W21811316 cites W1991655882 @default.
- W21811316 cites W1995330252 @default.
- W21811316 cites W1997761054 @default.
- W21811316 cites W1999468381 @default.
- W21811316 cites W2000398770 @default.
- W21811316 cites W2000661474 @default.
- W21811316 cites W2005908510 @default.
- W21811316 cites W2007676812 @default.
- W21811316 cites W2008943938 @default.
- W21811316 cites W2009287427 @default.
- W21811316 cites W2017550690 @default.
- W21811316 cites W2018856451 @default.
- W21811316 cites W2027851675 @default.
- W21811316 cites W2029064284 @default.
- W21811316 cites W2029761321 @default.
- W21811316 cites W2031875672 @default.
- W21811316 cites W2038504270 @default.
- W21811316 cites W2039217072 @default.
- W21811316 cites W2039559122 @default.
- W21811316 cites W2040452288 @default.
- W21811316 cites W2041559913 @default.
- W21811316 cites W2042898056 @default.
- W21811316 cites W2046835769 @default.
- W21811316 cites W2050180359 @default.
- W21811316 cites W2053482681 @default.
- W21811316 cites W2054569014 @default.
- W21811316 cites W2055248417 @default.
- W21811316 cites W2055366521 @default.
- W21811316 cites W2055385362 @default.
- W21811316 cites W2055864845 @default.
- W21811316 cites W2061102594 @default.
- W21811316 cites W2062786076 @default.
- W21811316 cites W2063866881 @default.
- W21811316 cites W2064357176 @default.
- W21811316 cites W2068323363 @default.
- W21811316 cites W2075223695 @default.
- W21811316 cites W2077757753 @default.
- W21811316 cites W2079247052 @default.
- W21811316 cites W2080470439 @default.
- W21811316 cites W2080785051 @default.
- W21811316 cites W2084427803 @default.
- W21811316 cites W2087646765 @default.
- W21811316 cites W2091564048 @default.
- W21811316 cites W2091665345 @default.
- W21811316 cites W2095647706 @default.
- W21811316 cites W2097750504 @default.
- W21811316 cites W2097854437 @default.
- W21811316 cites W2103053426 @default.
- W21811316 cites W2103245453 @default.
- W21811316 cites W2106981695 @default.
- W21811316 cites W2107195787 @default.
- W21811316 cites W2107549319 @default.
- W21811316 cites W2109814399 @default.
- W21811316 cites W2110145942 @default.
- W21811316 cites W2110167268 @default.
- W21811316 cites W2113002952 @default.
- W21811316 cites W2113089341 @default.
- W21811316 cites W2113118503 @default.
- W21811316 cites W2114775432 @default.
- W21811316 cites W2116548971 @default.
- W21811316 cites W2117807413 @default.
- W21811316 cites W2125791343 @default.
- W21811316 cites W2127211051 @default.
- W21811316 cites W2130582167 @default.
- W21811316 cites W2132505348 @default.
- W21811316 cites W2133217116 @default.
- W21811316 cites W2136489990 @default.
- W21811316 cites W2138986942 @default.
- W21811316 cites W2147797899 @default.
- W21811316 cites W2148984742 @default.
- W21811316 cites W2149388786 @default.
- W21811316 cites W2152412672 @default.